Bahrain inaugurated the first specialised clinic at the Al-Shamil Medical Centre to implement the new treatment protocol for active COVID-19 cases, using “Sotrovimab” and drugs that develop monoclonal antibodies, as part of the kingdom’s continuous efforts to combat the novel Coronavirus.
The minister also said that the visiting delegation from GSK will be informed closely about Bahrain’s experience, as well as train the medical staff on the guiding principles on using the right medicine and implementing the protocol of the new drug to achieve efficacy and maximum benefits.
Sotrovimab is dispensed to infected persons via the intravenous line (IV), under the medical supervision of government hospitals, and will not be available for sale in pharmacies or private hospitals.
It is to be noted that Bahrain’s National Health Regulatory Authority (NHRA) has approved “Sotrofimab” for emergency use, a new drug by GlaxoSmithKline (GSK) for the treatment of COVID-19.
The decision to add “Sotrovimab” to COVID-19 treatment protocols follows emergency use approval by the US Food and Drug Administration (FDA) as well a comprehensive review of GSK’s clinical trials.
“Sotrovimab-VIR-7831” develops “monoclonal antibodies” and is used to treat infected adults and adolescents with mild to moderate COVID-19 symptoms who are at risk of their condition deteriorating and resulting in hospitalisation.